Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 07-31 15:03:32 EDT

5.40

-0.36

-6.34%

High5.74	Low5.18	Vol537.23K
Open5.74	D1 Closing5.76	Amplitude9.72%
Mkt Cap168.81M	Tradable Cap91.06M	Total Shares31.29M
T/O2.86M	T/O Rate3.18%	Tradable Shares16.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.395,"timestamp":1785524609337,"preClose":5.76,"halted":0,"volume":537227,"delay":0,"changeRate":-0.0633680555555556,"floatShares":16877700,"shares":31289969,"eps":-3.661292,"marketStatus":"Trading","change":-0.365,"latestTime":"07-31 15:03:32 EDT","open":5.74,"high":5.74,"low":5.18,"amount":2855866.7132707997,"amplitude":0.097222,"askPrice":5.42,"askSize":1089,"bidPrice":5.37,"bidSize":234,"shortable":0,"etf":0,"ttmEps":-3.661292,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785528000000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.76,"preHourTrading":{"tag":"盘前","latestPrice":5.75,"preClose":5.76,"latestTime":"09:20 EDT","volume":2474,"amount":14622.961707,"timestamp":1785504016687,"change":-0.01,"changeRate":-0.001736,"amplitude":0.045156},"postHourTrading":{"tag":"盘后","latestPrice":5.79,"preClose":5.76,"latestTime":"19:34 EDT","volume":9685,"amount":55589.26,"timestamp":1785454450916,"change":0.03,"changeRate":0.005208,"amplitude":0.034722},"volumeRatio":0.702834,"impliedVol":0.5773,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2656128395","title":"BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2656128395","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656128395?lang=en_us&edition=fundamental","pubTime":"2026-08-01 02:36","pubTimestamp":1785522969,"startTime":"0","endTime":"0","summary":"Roger Song, an analyst from Jefferies, maintained the Buy rating on BioAge Labs, Inc.. The associated price target was lowered to $21.00. Roger Son...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-therapeutics-buy-rating-maintained-despite-cut-in-price-target-to-21-on-refined-ascvd-and-ocular-program-assumptions-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-therapeutics-buy-rating-maintained-despite-cut-in-price-target-to-21-on-refined-ascvd-and-ocular-program-assumptions-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655736487","title":"HighTide Therapeutics Launches Discounted Share Placing to Raise HK$225 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655736487","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655736487?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:37","pubTimestamp":1785505058,"startTime":"0","endTime":"0","summary":"Hightide Therapeutics Inc ( ($HK:2511) ) just unveiled an announcement. HighTide Therapeutics, Inc. has entered into a placing agreement with a sol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hightide-therapeutics-launches-discounted-share-placing-to-raise-hk225-million?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hightide-therapeutics-launches-discounted-share-placing-to-raise-hk225-million?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655364859","title":"Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $11 From $36, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655364859","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655364859?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:31","pubTimestamp":1785504663,"startTime":"0","endTime":"0","summary":"Bicycle Therapeutics (BCYC) has an average rating of overweight and mean price target of $10.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655657643","title":"Bicycle Therapeutics assumed with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655657643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655657643?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:00","pubTimestamp":1785499258,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jeff Jones assumed coverage of Bicycle Therapeutics (BCYC) with an Outperform rating with a price target of $11, down from $26....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655842365","title":"Qyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655842365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655842365?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:39","pubTimestamp":1785497995,"startTime":"0","endTime":"0","summary":"An update from Qyuns Therapeutics Co., Ltd. Class H ( ($HK:2509) ) is now available. Qyuns Therapeutics announced that its long-acting bispecific a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-wins-new-qx027n-trial-approvals-and-secures-global-licensing-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-wins-new-qx027n-trial-approvals-and-secures-global-licensing-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385448","title":"Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655385448?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441900,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., July  30, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336431/0/en/Trevi-Therapeutics-to-Report-Second-Quarter-2026-Financial-Results-and-Provide-a-Corporate-Update-on-August-6-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655388679","title":"Bicycle Therapeutics is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2655388679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655388679?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:26","pubTimestamp":1785439560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCYC/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655022318","title":"Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655022318","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655022318?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:05","pubTimestamp":1785431156,"startTime":"0","endTime":"0","summary":"13:00 EDT Atossa Therapeutics (ATOS) sees opportunities for (Z)-endoxifen beyond breast cancer Published first on TheFly – the ultimate source for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-sees-opportunities-for-z-endoxifen-beyond-breast-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-sees-opportunities-for-z-endoxifen-beyond-breast-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4548","BK4079","LENZ","BK4585","ATOS","BK4551","BK4588","Z","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655022598","title":"Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel","url":"https://stock-news.laohu8.com/highlight/detail?id=2655022598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655022598?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:05","pubTimestamp":1785431128,"startTime":"0","endTime":"0","summary":"In an exclusive interview, Atossa Therapeutics‘","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meet-atossa-therapeutics-fly-exclusive-with-cfo-mark-daniel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meet-atossa-therapeutics-fly-exclusive-with-cfo-mark-daniel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655017098","title":"Travere Therapeutics is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2655017098","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655017098?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:05","pubTimestamp":1785427500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFTY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872102","title":"Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872102","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872102?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335993/0/en/Aprea-Therapeutics-Provides-ACESOT-1051-Program-Update-for-WEE1-Inhibitor-APR-1051-Accelerating-and-Expanding-Enrollment-Clinical-Data-Presentation-Planned-for-Q4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872800","title":"Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872800?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:58","pubTimestamp":1785412720,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Tvardi Therapeutics ( ($TVRD) ). On July 30, 2026, Tvardi Therapeutics announced it had selected ulcerative col...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-targets-ulcerative-colitis-with-stat3-inhibitor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-targets-ulcerative-colitis-with-stat3-inhibitor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874423","title":"Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874423","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874423?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:56","pubTimestamp":1785412574,"startTime":"0","endTime":"0","summary":"Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60794994/bicycle-therapeutics-q2-eps-0-72-misses-0-59-estimate-sales-629-000k-miss-4-221m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655871929","title":"Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871929","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655871929?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:25","pubTimestamp":1785410700,"startTime":"0","endTime":"0","summary":"Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335930/0/en/Alterity-Therapeutics-Releases-Appendix-4C-Q4-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","IE00BKVL7J92.USD","LU2125909916.SGD","LU0149725797.USD","BK4539","LU2211815571.USD","LENZ","KOL","LU2237443549.SGD","LU2237443895.HKD","LU0757428866.USD","IE00BHPRN162.USD","LU1815336091.USD","IE00BFXG1179.USD","LU0728928796.USD","LU2125909759.SGD","LU1363072403.SGD","LU1923622291.USD","IE00B1BXHZ80.USD","CSF","BK4006","LU2237443622.USD","BK4007","LU0882574139.USD","MSA","LU0154245673.USD","LU0267386448.USD","LU0971096721.USD","LU0053671581.USD","LU2237443465.HKD","LU2746668974.SGD","LU2237443382.USD","LU0154245756.USD","BK4139","LU2237443978.SGD","LU2746668461.USD","IE00BZ1G4Q59.USD","CMC","LU0170899867.USD","BK4143"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655879421","title":"Maxim Downgrades Silexion Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655879421","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655879421?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:15","pubTimestamp":1785410131,"startTime":"0","endTime":"0","summary":"Maxim Downgrades Silexion Therapeutics to Hold From Buy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655287909","title":"Bicycle Therapeutics reports Q2 EPS (72c), consensus (58c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655287909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655287909?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:12","pubTimestamp":1785409944,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $629,000 vs. $2.92M last year. “We are pleased with the progress we made during the second quarter. Our financial discipline wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-reports-q2-eps-72c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-reports-q2-eps-72c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655879051","title":"Bicycle Therapeutics sees cash runway into 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2655879051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655879051?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:11","pubTimestamp":1785409917,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents were $510.1 million as of June 30, 2026, compared to $628.1 million as of December 31, 2025. The decrease in cash and cas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-sees-cash-runway-into-2030-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-sees-cash-runway-into-2030-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655841739","title":"Qyuns Therapeutics Partner Caldera to Merge with Synlogic","url":"https://stock-news.laohu8.com/highlight/detail?id=2655841739","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655841739?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:32","pubTimestamp":1785382325,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said its partner, Caldera Therapeutics, has agreed to merge with Synlogic in an all-stock transaction, according to a Wednesday Hong Kong bourse filing.The combined company is expected to list on the Nasdaq Capital Market under the ticker \"CALD.\"The deal is backed by a $278 million concurrent private placement to fund the development of QX030N/CLD-423 for ulcerative colitis, Crohn's disease and other immune-mediated diseases.Qyuns said it licensed global development and commercialization rights for QX030N/CLD-423 to Caldera in 2025 and currently holds about an 11.48% stake in the company.The merger is expected to close by early 2027, subject to shareholder, regulatory and other customary approvals.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","LENZ","BK4139","02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655612849","title":"Major Insider Move Signals Growing Confidence in Outlook Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2655612849","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655612849?lang=en_us&edition=fundamental","pubTime":"2026-07-30 10:05","pubTimestamp":1785377121,"startTime":"0","endTime":"0","summary":"New insider activity at Outlook Therapeutics ( ($OTLK) ) has taken place on July 29, 2026. Director Faisal Ghiath Sukhtian has strengthened his pos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-outlook-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-outlook-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892049","title":"Quince Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892049?lang=en_us&edition=fundamental","pubTime":"2026-07-30 00:34","pubTimestamp":1785342840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.1406},{"period":"1month","weight":0.0141},{"period":"3month","weight":-0.3514},{"period":"6month","weight":-0.6359},{"period":"1year","weight":-0.8127},{"period":"ytd","weight":-0.64}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.666667,"avgChangeRate":0.046581},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction